Phase 1a First-in-Human Study of Safety and Tolerability of ASV AGEN2017 With QS-21 Stimulon Adjuvant as a Single Agent in Subjects With Solid Tumor at Risk of Relapse Undergoing Observation as SOC Following Complete Surgical Resection
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2019
Price : $35 *
At a glance
- Drugs AutoSynVax (Primary) ; QS 21 (Primary)
- Indications Bladder cancer; Breast cancer; Cervical cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cancer; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Agenus
- 18 May 2019 Planned End Date changed from 1 Jun 2020 to 1 Dec 2020.
- 18 May 2019 Planned primary completion date changed from 1 Jan 2020 to 1 Aug 2020.
- 31 Oct 2018 Status changed from not yet recruiting to recruiting.